Skip to content

Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System

Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03503162
Enrollment
95
Registered
2018-04-19
Start date
2018-05-17
Completion date
2019-05-20
Last updated
2021-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Gastrointestinal Disease

Keywords

bowel prepartion

Brief summary

The aim of this study is to evaluate the potential improvement in colonoscopy procedure's outcomes when using the Pure-Vu System in hospitalized patients who are indicated for colonoscopy procedure.

Detailed description

This multi-center, prospective, single arm study will include up to 100 patients (20-40 patients per site), aimed at evaluating the performance of the Pure-Vu System in cleansing hospitalized patients' colon who are indicated for standard colonoscopy procedure. Subjects will be enrolled at up to 4 clinical sites in the United States and Europe. Subjects who meet the eligibility criteria will be prescribed a standard bowel preparation bowel preparation regimen including diet restrictions and oral bowel preparation. Following the bowel preparation, the patient will undergo colonoscopy with the Pure-Vu system. In case of inadequate bowel preparation, as per the nurse report and / or BBPS \< 2, in at least one of the colon segments, prior Pure-Vu use, the physician will complete a questionnaire on the patient's management standard of care assuming the absence of Pure-Vu. Follow-up will be conducted at 48 hours (± 48 hours) post procedure.

Interventions

The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.

Sponsors

Motus GI Medical Technologies Ltd
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Hospitalized patients who are indicated for a screening, diagnostic, surveillance or therapeutic colonoscopy 2. Patients' age \> 22 years 3. Patient has signed the informed consent

Exclusion criteria

1. Patients with known Inflammatory Bowel Disease and / or active Colitis 2. Patients with active diverticulitis 3. Patients with known or detected (during colonoscopy) bowel obstruction 4. Patients with BMI ≤ 18 5. Patients with ascites Child Pugh C 6. Patients who are 30 days post-transplant 7. Patients treated with Peritoneal dialysis 8. Patients under active IV inotropic medications 9. Patients with LVAD 10. Patients who have active anticoagulant medications (excluding aspirin) or dual antiplatelet therapy in their system prior to the procedure. (Note: to avoid exclusion therapy should be discontinued 48 hours or greater prior to the procedure based on discretion of physician) 11. Subjects with known coagulation disorder (INR ≥ 2 or platelets \<50,000) 12. Subjects with hemodynamic instability. 13. Pregnancy (as stated by patient) or breast feeding 14. Subjects with altered mental status/inability to provide informed consent 15. Patients who have participated in another interventional clinical study in the last 2 months

Design outcomes

Primary

MeasureTime frameDescription
The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu Systemup to 2 hoursThe rate of adequate cleansing level in each colon segment before and after use of Pure-Vu will be evaluated using the Boston Bowel Preparation Scale (BBPS). Segment score of 0-3 given to each of the 3 segments of the colon (Left side, Transverse and right side) summed for the maximum score of 9 (0= dirtiest and 9= pristine). An adequate cleansing procedure will be considered when all the colon segments will be graded as 2 or above.

Countries

United States

Participant flow

Participants by arm

ArmCount
Colonoscopy With Pure-Vu System
Inpatient colonoscopies with Pure-Vu System- Single Arm Pure-Vu System: The Pure-Vu System is FDA cleared device intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
94
Total94

Withdrawals & dropouts

PeriodReasonFG000
Overall Studydid not meet eligibility1

Baseline characteristics

CharacteristicColonoscopy With Pure-Vu System
Age, Customized62.44 years
Race and Ethnicity Not Collected— Participants
Region of Enrollment
Germany
25 participants
Region of Enrollment
United States
69 participants
Sex: Female, Male
Female
38 Participants
Sex: Female, Male
Male
56 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 94
other
Total, other adverse events
3 / 94
serious
Total, serious adverse events
1 / 94

Outcome results

Primary

The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu System

The rate of adequate cleansing level in each colon segment before and after use of Pure-Vu will be evaluated using the Boston Bowel Preparation Scale (BBPS). Segment score of 0-3 given to each of the 3 segments of the colon (Left side, Transverse and right side) summed for the maximum score of 9 (0= dirtiest and 9= pristine). An adequate cleansing procedure will be considered when all the colon segments will be graded as 2 or above.

Time frame: up to 2 hours

Population: Rate of Adequacy of bowel preparation using the Boston Bowel Preparation Score (BBPS)

ArmMeasureGroupValue (MEAN)
Colonoscopy With Pure-Vu SystemThe Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu SystemRate of adequate preparation measured by BBPS before Pure-Vu Use38 Percentage of Adequate cleansing
Colonoscopy With Pure-Vu SystemThe Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu SystemRate of adequate preparation measured by BBPS after Pure-Vu Use96 Percentage of Adequate cleansing

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026